Daniel Castellano, Medical Oncologist at Hospital Universitario 12 de Octubre, shared a post on X:
“How to apply the current evidence in the treatment of mCSPC!! Excellent review.-
The new molecular precision “triplet intensification” is here. .- A HRR (BRCA2+) alt and pTEN loss population have a poor prognosis. .- We need to better biomarkers profile in this setting.”
Title: Personalized intensification of treatment for hormone-sensitive prostate cancer
Authors: Michael A. Cilento, Lisa M. Butler, Louise Emmett, Christopher J. Sweeney
Read the Full Article.
More from Daniel Castellano on OncoDaily.
